Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the
past 3–4 decades with generally poor outcomes, especially in elderly populations unfit for …

Highlights•AML is a highly heterogeneous disease and warrants an individualized
approach.•The advent of effective low-intensity regimens has improved outcomes in older …

Acute myeloid leukemia (AML) is a heterogenous and complex disease characterized by
rapid cellular proliferation, an aggressive clinical course, and generally high mortality. While …

High-risk acute myeloid leukemia (AML) is defined by clinical and biologic features that
predict for poor response to induction chemotherapy and high risk of relapse. Despite even …

Abstract Purpose of Review The extensive genomic characterization of acute myeloid
leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We …

In recent decades, therapy for acute myeloid leukemia (AML) has remained relatively
unchanged, with chemotherapy regimens primarily consisting of an induction regimen …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

The therapeutic landscape is rapidly changing, with eight new drugs approved by the Food
and Drug Administration within the last 2 years, including midostaurin and gilteritinib for …